Nitrovasodilators and cGMP inhibit human platelet activation

Area of Science:

• Biochemistry
• Pharmacology
• Hematology

Background:

• Endothelial relaxing factor is nitric oxide (NO), synthesized from L-arginine by nitric oxide synthase.
• NO inhibits platelet aggregation and adhesion by activating soluble guanylate cyclase, increasing cyclic GMP (cGMP) levels.
• Nitrovasodilators like sodium nitroprusside release NO.

Purpose of the Study:

• To investigate the effects of sodium nitroprusside and a permeable cGMP derivative on human platelet aggregation and ATP secretion.
• To examine these effects on platelets stimulated by protein kinase C activators and calcium ionophores.

Main Methods:

• Human platelets were pretreated with lysine acetylsalicylate, washed, and resuspended.
• Platelet aggregation and adenosine triphosphate (ATP) secretion were measured.
• Stimulation was achieved using protein kinase C activators (1-oleoyl-2-acetylglycerol or phorbol ester) or the calcium ionophore ionomycin.
• Experiments were conducted in the presence of a cGMP phosphodiesterase inhibitor (M&B 22948).
• The effect of hemoglobin on nitroprusside's inhibitory action was assessed.

Main Results:

• Sodium nitroprusside and 8-Br-cGMP dose-dependently inhibited platelet aggregation and ATP secretion induced by protein kinase C activators.
• These inhibitory effects were observed in the presence of a cGMP phosphodiesterase inhibitor.
• Hemoglobin reversed the inhibitory effect of sodium nitroprusside, confirming the role of NO.
• Sodium nitroprusside also dose-dependently inhibited aggregation and ATP secretion induced by ionomycin.
• The inhibition of ionomycin-evoked responses indicates an effect on the calcium-dependent pathway.

Conclusions:

• Cyclic GMP (cGMP) effectively inhibits both protein kinase C-dependent and calcium-dependent pathways of human platelet activation.
• These findings highlight the role of the NO-cGMP pathway in regulating platelet function.